Medical devices giant Becton Dickinson (BD) has agreed to buy automation and infection prevention specialist CareFusion for over $12 billion (£7.5 billion) in a mixture of shares and borrowed cash.
CareFusion develops technology for reducing drug dispensing errors by automation, and for preventing and detecting infections.
BD says that Carefusion’s products are complementary to its own ranges, and its distribution infrastructure will allow the merged company to increase global sales and cut supply chain costs.
The move follows other consolidation between major players in the medical devices segment, including Medtronic’s $43 billion purchase of Covidien in June.
Source: Chemistry World
Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.
GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.
A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.
